About Paul Scherrer Institute
PSI operates the first compact scanning gantry worldwide for proton radiation therapy of deep-seated tumors. The spot-scanning technique developed at PSI enables malignant tumors to be targeted with high precision deep inside in the body without damaging healthy tissue around the target area. By end of 2011, the PSI compact Gantry 1 had been used to treat nearly 1000 patients suffering from brain, skull-base or spinal cord tumors as well as abdominal sarcomas. Among the patients were more than 350 children and young people under the age of 20. PSI has treated children since 2004.

Forward-Looking Statements

Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's future orders, revenues or other financial performance; the ability of the company's technology and products to treat cancer; and any statements using the terms "will," "plan," "expect," "estimated," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of global economic conditions; demand for the company's products; the company's ability to develop, commercialize, and deploy new products; the company's ability to meet legal and regulatory requirements; changes in the legal or regulatory environment; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

FOR INFORMATION CONTACT:
Neil Madle, +44 7786 526068
neil.madle@varian.com

SOURCE Varian Medical Systems

Back to HCB News

More HCB News